Skip to Content

New Oral Drug Sotyktu for Plaque Psoriasis Patients Demonstrates Promising Results with Favorable Safety Profile

According to Professor Enikö Sonkoly, the POETYK2 STUDY received a great deal of attention at EADV2023, as several presentations and posters reviewed the efficacy and safety of deucravacitinib, a new oral drug for the treatment of chronic plaque psoriasis. In this MEDtalk, she elaborates on the findings from the study and explains the mechanisms of the TYK2 inhibitor.

Enikö Sonkoly

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top